# GLP-1 Drugs **GLP-1 drugs** are the class of diabetes-and-obesity medicines that became the defining [[Drug Pricing]] flashpoint of the decade: [[Novo Nordisk]]'s **semaglutide** (Ozempic, Wegovy) and [[Eli Lilly]]'s **tirzepatide** (Mounjaro, Zepbound). Their combination of huge demand, high list prices, and mass-market appeal made them the single drug class where every pricing mechanism collides. ## Why It Matters GLP-1s are the test case for the whole system at once: - **[[Formulary]] power** — CVS Caremark dropped Zepbound for Wegovy in 2025, moving the market overnight (see [[CVS Health]]). - **[[Drug Price Negotiation]]** — the Ozempic/Wegovy family is in the second IRA negotiation cohort, with prices effective 2027. - **[[Most-Favored-Nation Drug Pricing Deals]] + TrumpRx** — the Trump administration struck deals with Lilly and Novo for MFN-aligned pricing and direct-to-consumer sales (GLP-1 vials around $350/month, first oral versions near $149/month), paired with multibillion-dollar U.S. manufacturing pledges. They also sit at the [[MAHA]] intersection of obesity politics, diet, and pharma skepticism. GLP-1s are where drug-pricing policy becomes mass-market kitchen-table economics. See [[Drug Pricing]].